Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitochondrial Toxicity of TAF vs TDF in HIV
NCT03251144Phase 2Completed
- Sponsor
- University of California, Los Angeles
- Start
- Apr 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by University of California, Los Angeles. Primary endpoint: Change in Mitochondrial Function [Cellular Oxygen Consumption (COC)] at 12 months. Started Apr 2019; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03251144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251144.